Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases

Therapeutic Advances in Gastroenterology

Volumn 8, Issue 2, 2015, Pages 66-82

  Amiot, Aurelien ^a   Peyrin Biroulet, Laurent ^b  

^a University of Paris Est Créteil   (France)

^b CHU NANCY BRABOIS   (France)

Author keywords

anti TNF agents; biologics; Crohn s disease; inflammatory bowel diseases; ulcerative colitis

Indexed keywords

ADALIMUMAB; ALICAFORSEN; ANRUKINZUMAB; AZATHIOPRINE; BERTILIMUMAB; CERTOLIZUMAB PEGOL; CPT 13; CYTOKINE RECEPTOR ANTAGONIST; ETROLIZUMAB; FILGOTINIB; FINGOLIMOD; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 6 ANTIBODY; JANUS KINASE INHIBITOR; LAQUINIMOD; MASITINIB; NATALIZUMAB; PEFICITINIB; PF 04236921; PLACEBO; QAX 576; TOFACITINIB; TRALOKINUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; VATELIZUMAB; VEDOLIZUMAB;

CROHN DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; HUMAN; INFLAMMATORY BOWEL DISEASE; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; ULCERATIVE COLITIS;

EID: 84922368916     PISSN: 1756283X     EISSN: 17562848     Source Type: Journal    
DOI: 10.1177/1756283X14558193     Document Type: Review

References (89)

1. Asthana A. Sparrow M. Peyrin-Biroulet L. (2014) Optimizing conventional medical therapies in inflammatory bowel disease. Cur Drug Targets Sep 14 [Epub ahead of print].
2. Billioud V. Sandborn W. Peyrin-Biroulet L. (2011). Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 106: 674–684.
3. Beunk L. Verwoerd A. van Overveld F. Rijkers G. (2013) Role of mast cells in mucosal diseases: current concepts and strategies for treatment. Expert Rev Clin Immunol 9: 53–63.
4. Burger D. Travis S. (2011) Conventional medical management of inflammatory bowel disease. Gastroenterology 140: 1827–1837 e1822.
5. Choy E. Hazleman B. Smith M. Moss K. Lisi L. Scott D. et al. (2002) Efficacy of a novel pegylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 41: 1133–1137.
6. Colombel J.F. Sandborn W.J. Rutgeerts P. Enns R. Hanauer S.B. Panaccione R. et al. (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. http://www.ncbi.nlm.nih.gov/pubmed/17241859 Gastroenterology 132: 52-65.
7. Comi G. Jeffery D. Kappos L. Montalban X. Boyko A. Rocca M. et al. (2012) Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 366: 1000–1009.
8. Coskun M. Salem M. Pedersen J. Nielsen O. (2013) Involvement of Jak / Stat signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res 76: 1–8.
9. Crommelin D. Storm G. Verrijk R. de Leede L. Jiskoot W. Hennink W. (2003) Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. Int J Pharm 266: 3–16.
10. D'allard D. Gay J. Descarpentries C. Frisan E. Adam K. Verdier F. et al. (2013) Tyrosine kinase inhibitors induce down-regulation of c-kit by targeting the ATP pocket. PloS ONE 8: e60961.
11. D'haens G. Colombel J. Sandborn W. Rutgeerts P. Feagan B. (2013) Safety and efficacy of laquinimod in inducing clinical and biochemical improvement in active Crohn's disease: results of an exploratory trial. Gastroenterology 144: S21.
12. D'haens G. Panaccione R. Higgins P. Vermeire S. Gassull M. Chowers Y. et al. (2011) The London position of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 106: 199–212.
13. Danese S. (2012) New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 61: 918–932.
14. Danese S. Rudzinski J. Brandt W. Dupas J. Peyrin-Biroulet L. Bouhnik Y. et al. (2014) Tralokinumab (CAT-354), an interleukin 13 antibody, in moderate to severe ulcerative colitis: a phase 2a randomized placebo-controlled study. Gastroenterology 146: S149.
15. Delavallee L. Le Buanec H. Bessis N. Assier E. Denys A. Bizzini B. et al. (2008) Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalpha. Ann Rheum Dis 67: 1332–1338.
16. Dewit O. Hebuterne X. Dupas J. Howaldt S. Bures J. Schreiber S. et al. (2012) Results of a phase II, randomized, double blind, controlled trial of the efficacy of active therapeutic immunization with TNF-Kinoid in patients with moderate to severe Crohn's disease with secondary resistance to TNFα antagonist. Gastroenterology 142: S-567-S-568.
17. European Medicines Agency (2013) Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/06/WC500144124.pdf.
18. European Medicines Agency (2013) Inflectra – Summary of Opinion (Initial Authorisation). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002778/WC500144831.pdf.
19. European Medicines Agency (2013) Refusal of the Marketing Authorisation for Xeljanz (Tofacitinib). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002542/WC500146629.pdf.
20. European Medicines Agency (1995–2014) Clinical trials register. http://www.clinicaltrialsregister.eu (accessed June 2014).
21. Farkas K. Lakatos P. Nagy F. Szepes Z. Miheller P. Papp M. et al. (2013) Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy. Scand J Gastroenterol 48: 1394–1398.
22. Feagan B. Greenberg G. Wild G. Fedorak R. Pare P. Mcdonald J. et al. (2005) Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 352: 2499–2507.
23. Feagan B. Greenberg G. Wild G. Fedorak R. Pare P. Mcdonald J. et al. (2008 a) Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 6: 1370–1377.
24. Feagan B. Panaccione R. Sandborn W. D'haens G. Schreiber S. Rutgeerts P. et al. (2008 b) Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 135: 1493–1499.
25. Feagan B. Rutgeerts P. Sands B. Hanauer S. Colombel J. Sandborn W. et al. (2013) Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369: 699–710.
26. Ghosh S. Goldin E. Gordon F. Malchow H. Rask-Madsen J. Rutgeerts P. et al. (2003) Natalizumab for active Crohn's disease. N Engl J Med 348: 24–32.
27. Gottlieb A. Menter A. Mendelsohn A. Shen Y. Li S. Guzzo C. et al. (2009) Ustekinumab, a human interleukin 12 / 23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373: 633–640.
28. Hanauer S.B. Feagan B.G. Lichtenstein G.R. Mayer L.F. Schreiber S. Colombel J.F. et al. (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359: 1541–1549.
29. Hanauer S.B. Sandborn W.J. Rutgeerts P. Fedorak R.N. Lukas M. MacIntosh D. et al. (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130: 323–333.
30. ICH (2004) Comparability of biotechnological / biological products subject to changes in their manufacturing process. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guideline.pdf
31. Ito H. Takazoe M. Fukuda Y. Hibi T. Kusugami K. Andoh A. et al. (2004) A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126: 989–996; discussion 947.
32. Kavanaugh A. van der Heijde D. Mcinnes I. Mease P. Krueger G. Gladman D. et al. (2012) Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum 64: 2504–2517.
33. Kay J. Matteson E. Dasgupta B. Nash P. Durez P. Hall S. et al. (2008) Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 58: 964–975.
34. Kleinschmidt-Demasters B. Tyler K. (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353: 369–374.
35. Langer-Gould A. Atlas S. Green A. Bollen A. Pelletier D. (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353: 375–381.
36. Lautenschlager C. Schmidt C. Fischer D. Stallmach A. (2013) Drug delivery strategies in the therapy of inflammatory bowel disease. Adv Drug Deliv Rev, in press.
37. Lawrence M. Springer T. (1991) Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell 65: 859–873.
38. Leonardi C. Kimball A. Papp K. Yeilding N. Guzzo C. Wang Y. et al. (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371: 1665–1674.
39. Lobaton T. Vermeire S. van Assche G. Rutgeerts P. (2014) Review article: Anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther 39: 579–594.
40. Malik N. (2009) Controlling the cost of innovative cancer therapeutics. Nat Rev Clin Oncol 6: 550–552.
41. Mannon P. Reinisch W. (2012) Interleukin 13 and its role in gut defence and inflammation. Gut 61: 1765–1773.
42. Michelsen K. Wong M. Ko B. Thomas L. Dhall D. Targan S. (2013) HMPL-004 (Andrographis paniculata extract) prevents development of murine colitis by inhibiting T-cell proliferation and Th1/Th17 responses. Inflamm Bowel Dis 19: 151–164.
43. Monteleone G. Fantini M. Onali S. Zorzi F. Sancesario G. Bernardini S. et al. (2012) Phase I clinical trial of Smad 7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Mol Ther 20: 870–876.
44. Monteleone G. Kumberova A. Croft N. Mckenzie C. Steer H. Macdonald T. (2001) Blocking Smad 7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 108: 601–609.
45. Mudter J. Neurath M. (2007) Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm Bowel Dis 13: 1016–1023.
46. Papp K. Langley R. Lebwohl M. Krueger G. Szapary P. Yeilding N. et al. (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371: 1675–1684.
47. Parikh A. Leach T. Wyant T. Scholz C. Sankoh S. Mould D. et al. (2012) Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 18: 1470–1479.
48. Park W. Hrycaj P. Jeka S. Kovalenko V. Lysenko G. Miranda P. et al. (2013) A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: The PLANETAS Study. Ann Rheum Dis 72: 1605–1612.
49. Peyrin-Biroulet L. (2008) Crohn's disease: beyond antagonists of tumor necrosis factor. Lancet 372: 67–81.
50. Peyrin-Biroulet L. Cieza A. Sandborn W.J. Coenen M. Chowers Y. Hibi T. et al. (2012) Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. International Programme to Develop New Indexes for Crohn's Disease (IPNIC) group. Gut 61: 241–247.
51. Peyrin-Biroulet L. Loftus E. Jr Colombel J. Sandborn W. (2009) The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 105: 289–297.
52. Peyrin-Biroulet L. (2013) Disease-modifying anti-inflammatory bowel disease drugs (DMAIDs): the missing term in the literature. Am J Gastroenterol 108: 859–860.
53. Peyrin-Biroulet L. Danese S. (2013) Tofacitinib: Janus bifrons in ulcerative colitis treatment. Gastroenterology 144: 1136–1138.
54. Praditpornsilpa K. Tiranathanagul K. Kupatawintu P. Jootar S. Intragumtornchai T. Tungsanga K. et al. (2011) Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int 80: 88–92.
55. Reinisch W. Panes J. Page K. Khurana S. Hua F. Comer G. et al. (2014) Discrepancy between fecal biomarkers and their intestinal gene expression in ulcerative colitis: results from an anti-IL-13 antibody study. J Crohns Colitis 8: S283.
56. Riese R. Krishnaswami S. Kremer J. (2010) Inhibition of Jak kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol 24: 513–526.
57. Rinaudo-Gaujous M. Paul S. Tedesco E. Genin C. Roblin X. Peyrin-Biroulet L. (2013) Review article: Biosimilars are the next generation of drugs for liver and gastrointestinal diseases. Aliment Pharmacol Ther 38: 914–924.
58. Rutgeerts P. Sandborn W. Feagan B. Reinisch W. Olson A. Johanns J. et al. (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353: 2462–2476.
59. Sandborn W. Colombel J. Enns R. Feagan B. Hanauer S. Lawrance I. et al. (2005) Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353: 1912–1925.
60. Sandborn W. Colombel J. Frankel M. Hommes D. Lowder J. Mayer L. et al. (2010) Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut 59: 1485–1492.
61. Sandborn W. Feagan B. Fedorak R. Scherl E. Fleisher M. Katz S. et al. (2008) A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135: 1130–1141.
62. Sandborn W. Feagan B. Marano C. Zhang H. Strauss R. Johanns J. et al. (2014 a) Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146: 85–95; quiz e14–85.
63. Sandborn W. Feagan B. Marano C. Zhang H. Strauss R. Johanns J. et al. (2014 b) Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146: 96–109 e101.
64. Sandborn W. Feagan B. Rutgeerts P. Hanauer S. Colombel J. Sands B. et al. (2013) Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 369: 711–721.
65. Sandborn W. Gasink C. Gao L. Blank M. Johanns J. Guzzo C. et al. (2012 a) Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 367: 1519–1528.
66. Sandborn W. Ghosh S. Panes J. Vranic I. Su C. Rousell S. et al. (2012 b) Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 367: 616–624.
67. Sandborn W.J. Feagan B.G. Marano C. Zhang H. Strauss R. Johanns J. et al. (2014) Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146: 96–109.
68. Sandborn W.J. Rutgeerts P. Enns R. Hanauer S.B. Colombel J.F. Panaccione R. et al. (2007) Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146: 829–838.
69. Sandborn W.J. van Assche G. Reinisch W. Colombel J.F. D'Haens G. Wolf D.C. et al. (2012) Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142: 257–265.
70. Sands B. Feagan B. Rutgeerts P. Colombel J. Sandborn W. Sy R. et al. (2013) Vedolizumab induction therapy for patients with Crohn's disease and prior anti-tumour necrosis factor antagonist failure: a randomised, placebo-controlled, double-blind, multicentre trial. J Crohns Colitis 7: S5–S6.
71. Schreiber S. Khaliq-Kareemi M. Lawrance I.C. Thomsen O.Ø. Hanauer S.B. McColm J. et al. (2007) Maintenance therapy with certolizumab pegol for Crohn's disease. http://www.ncbi.nlm.nih.gov/pubmed/17634459 N Engl J Med 357: 239–250.
72. Schreiber S. Rutgeerts P. Fedorak R.N. Khaliq-Kareemi M. Kamm M.A. Boivin M. et al. (2005) A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology http://www.ncbi.nlm.nih.gov/pubmed/?term=schreiber+2005+certolizumab 129: 807–818.
73. Singh J. Beg S. Lopez-Olivo M. (2010) Tocilizumab for rheumatoid arthritis. Cochrane Database Syst Rev CD008331.
74. Targan S. Feagan B. Fedorak R. Lashner B. Panaccione R. Present D. et al. (2007) Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 132: 1672–1683.
75. Targan S.R. Hanauer S.B. van Deventer S.J. Mayer L. Present D.H. Braakman T. et al. (1997) A short-term study of chimeric monoclonal antibody cA 2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA 2 Study Group. N Engl J Med 337: 1029–1035.
76. Tebib J. Mariette X. Bourgeois P. Flipo R. Gaudin P. Le Loet X. et al. (2009) Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. Arthritis Res Ther 11: R95.
77. US Food and Drug Administration (2009) Natalizumab: Highlights of Prescribing Information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125104s106lbl.pdf
78. US Food and Drug Administration (2012) Advisory Committee Meeting. Tofacitinib for the Treatment of Rheumatoid Arthritis. NDA 203214. Briefing Document. Available at: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/arthritisadvisorycommittee/ucm302960.pdf.
79. US Food and Drug Administration (2013) Draft Guidance on Biosimilar Product Development. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/default.html.
80. US National Institutes of Health (2011) Clinicaltrials.Gov. http://www.clinicaltrials.gov (accessed June 2014).
81. van Assche G. van Ranst M. Sciot R. Dubois B. Vermeire S. Noman M. et al. (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353: 362–368.
82. Varrin-Doyer M. Zamvil S. Schulze-Topphoff U. (2014) Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis. Exp Neurol, in press:
83. Vermeire S. O'byrne S. Keir M. Williams M. Lu T. Mansfield J. et al. (2014) Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet, in press.
84. Vestweber D. Blanks J. (1999) Mechanisms that regulate the function of the selectins and their ligands. Physiol Rev 79: 181–213.
85. Vignali D. Kuchroo V. (2012) IL-12 family cytokines: immunological playmakers. Nat Immunol 13: 722–728.
86. Weise M. Bielsky M. de Smet K. Ehmann F. Ekman N. Giezen T. et al. (2012) Biosimilars: what clinicians should know. Blood 120: 5111–5117.
87. Wernersson S. Pejler G. (2014) Mast cell secretory granules: armed for battle. Nat Rev Immunol 14: 478–494.
88. Yoo D. Hrycaj P. Miranda P. Ramiterre E. Piotrowski M. Shevchuk S. et al. (2013) A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: The PLANETRA Study. Ann Rheum Dis 72: 1613–1620.
89. Zhou H. Jang H. Fleischmann R. Bouman-Thio E. Xu Z. Marini J. et al. (2007) Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol 47: 383–396.